Results 181 to 190 of about 27,196 (258)

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo. [PDF]

Am J Hematol
Xiong S, Wais T, Varga C, Schueller C, Achyutuni S, Kralovics R.   +5 more
europepmc   +1 more source

Cutaneous Toxicities Associated With Amivantamab in Patients With Non‐Small Cell Lung Cancer: A Systematic Review

International Journal of Dermatology, EarlyView.
Ioannis‐Alexios Koumprentziotis, Aikaterini Bakella, Antonis Tsimpidakis, Alexander Stratigos, Vasiliki Nikolaou   +4 more
wiley   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2162-2170, July 2026.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy. [PDF]

J Immunother Cancer
Hou L, Jiao D, Dai H, Zhang J, Wang L, Gong X, Qi C, Guo X, Liu Z.   +8 more
europepmc   +1 more source

Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B‐ALL After CAR‐T Therapy and HSCT: A Case Series

Cancer Reports, Volume 9, Issue 7, July 2026.
ABSTRACT Background Although inotuzumab ozogamicin (InO) has been approved as an effective agent for patients with refractory/relapsed (r/r) B‐cell acute lymphoblastic leukemia (B‐ALL), data in the context of post chimeric antigen receptor (CAR)‐T cell therapy and allogeneic hematopoietic stem cell transplantation (allo‐HSCT) relapse are lacking.
Honghu Li, Luxin Yang, Lizhen Liu, Xiaoyu Lai, Lixia Zhu, Kui Zhao, Qian Luo, He Huang, Yi Luo   +8 more
wiley   +1 more source

Preclinical characterization of IBD0333, a novel CD24×4-1BB bispecific antibody with tumor-dependent agonistic activity for cancer immunotherapy. [PDF]

Antib Ther
Jiang DC, Zhou DD, Xu XR, Jiang XL, Yin LS, Zhong CY, Miao QF.   +6 more
europepmc   +1 more source

Exceptionally broad HIV-1 neutralization via bispecific antibody-mediated prepositioning. [PDF]

Proc Natl Acad Sci U S A
Kim S, Travisano KA, Wilder B, Palomares M, Cao Z, Seaman MS, Kim PS.   +6 more
europepmc   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Next-generation FVIIIa-mimetic bispecific antibody NXT007: evaluation in preclinical models of hemostasis and thrombosis. [PDF]

Blood Adv
Locke M, Albiez J, Receveur N, Marbach S, Frey N, Girotra M, Wyssenbach M, Bektic L, David T.   +8 more
europepmc   +1 more source